īerdy J (2005) Bioactive microbial metabolites. īassarello C, Lazzaroni S, Bifulco G, Lo Cantore P, Iacobellis NS, Riccio R, Gomez-Paloma L, Evidente A (2004) Tolaasins A–E, five new lipodepsipeptides produced by Pseudomonas tolaasii. īalan SS, Kumar CG, Jayalakshmi S (2016) Pontifactin, a new lipopeptide biosurfactant produced by a marine Pontibacter korlensis, strain SBK-47: purification, characterization and its biological evaluation. DSS73 is required for efficient biological containment of the root-pathogenic microfungi Rhizoctonia solani and Pythium ultimum. The current and potential therapeutic applications of these peptides, including structures and antituberculotic, anti-cyanobacterial, antifungal, antibacterial, antiviral, insecticidal, and antiprotozoal activities are discussed.Īndersen JB, Koch B, Nielsen TH, Sørensen D, Hansen M, Nybroe O, Christophersen C, Sørensen J, Molin S, Givskov M (2003) Surface motility in Pseudomonas sp. nine aromatic peptides eight glycopeptides 45 different cyclic lipopeptides 24 linear lipopeptides eight thiopeptides one lasso peptide ten typical cyclic peptides and five standard linear peptides.
The need for novel lead antibiotic compounds is urgent due to increasing drug resistance, and this review summarises 150 Gram-negative bacilli-derived compounds reported since 2000, including 40 cyclic lipopeptides from Pseudomonas spp. produce an enormous array of short peptides of 30 residues or fewer that are potential pharmaceutical drugs and/or biocontrol agents.
Gram-negative bacilli such as Pseudomonas spp., Pseudoalteromonas sp., Angiococcus sp., Archangium sp., Burkholderia spp., Chromobacterium sp., Chondromyces sp., Cystobacter sp., Jahnella sp., Janthinobacterium sp., Lysobacter spp., Paraliomyxa sp., Photobacterium spp., Photorhabdus sp., Pontibacter sp., Ruegeria sp., Serratia sp., Sorangium sp., Sphingomonas sp., and Xenorhabdus spp.
0 kommentar(er)
